You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Litigation Details for Pharmacyclics LLC v. Alvogen Pine Brook, LLC (D. Del. 2020)


✉ Email this page to a colleague

« Back to Dashboard


Pharmacyclics LLC v. Alvogen Pine Brook, LLC (D. Del. 2020)

Docket ⤷  Try a Trial Date Filed 2020-03-20
Court District Court, D. Delaware Date Terminated 2021-04-13
Cause 35:271 Patent Infringement Assigned To Colm Felix Connolly
Jury Demand Defendant Referred To
Parties LEK PHARMACEUTICALS D.D.
Patents 10,010,507; 10,213,386; 10,463,668; 10,478,439; 7,514,444; 8,008,309; 8,476,284; 8,497,277; 8,501,751; 8,697,711; 8,703,780; 8,735,403; 8,754,090; 8,754,091; 8,952,015; 8,987,421; 8,999,999; 9,125,889; 9,296,753; 9,540,382; 9,655,857; 9,713,617; 9,725,455; 9,795,604
Attorneys Jonathan R. Pepin
Firms Young, Conaway, Stargatt & Taylor LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Pharmacyclics LLC v. Alvogen Pine Brook, LLC
The small molecule drug covered by the patents cited in this case is ⤷  Try a Trial .
Biologic Drugs cited in Pharmacyclics LLC v. Alvogen Pine Brook, LLC

Details for Pharmacyclics LLC v. Alvogen Pine Brook, LLC (D. Del. 2020)

Date Filed Document No. Description Snippet Link To Document
2020-03-20 1 Complaint prior to the expiration of U.S. Patent No. 10,478,439 (“the ’439 Patent”). Zydus has submitted amendments…. This action for patent infringement, brought pursuant to the patent laws of the United States…action for infringement of the ’439 Patent. 3. Other patent infringement actions relating to…46. This civil action for patent infringement arises under the patent laws of the United States, including… THE ASSERTED PATENT 102. The ’439 Patent, entitled “Use of Inhibitors of External link to document
2020-04-27 19 Complaint - Amended expiration of the ’439 Patent and U.S. Patent No. 10,463,668 (“the ’668 Patent”). Alvogen- Natco has …. This action for patent infringement, brought pursuant to the patent laws of the United States…prior to the expiration of U.S. Patent No. 10,478,439 (“the ’439 Patent”). Zydus has submitted amendments…infringement of the ’439 and ’668 Patents. 3. Other patent infringement actions relating to…The ’439 Patent is listed in the Orange Book for IMBRUVICA®. 12. The ’668 Patent is listed External link to document
2020-04-27 20 Patent/Trademark Report to Commissioner of Patents the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,463,668 . (Blumenfeld, Jack…2020 13 April 2021 1:20-cv-00403 835 Patent - Abbreviated New Drug Application(ANDA) Defendant External link to document
2020-10-14 52 Complaint - Amended ” Curr HematolMalig Rep , 8 ( 1 ): 10,010,507 B1 * 7/2018 Chong A61K 9… ’439 Patent, the ’634 Patent, U.S. Patent No. 10,463,668 (“the ’668 Patent”), and U.S. Patent No. 10,695,350…of U.S. Patent No. 10,478,439 (“the ’439 Patent”), U.S. Patent No. 10,653,696 (“the ’696 Patent”), and… date of the ’439 Patent, ’668 Patent, ’634 Patent, or ’350 Patent or any later …exclusivity for the ’439 Patent, ’668 Patent, ’634 Patent, or ’350 Patent including any extensions External link to document
2020-10-26 59 Patent/Trademark Report to Commissioner of Patents the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,463,668 B2 ;10,653,696 B2 …2020 13 April 2021 1:20-cv-00403 835 Patent - Abbreviated New Drug Application(ANDA) Defendant External link to document
2020-03-20 6 Patent/Trademark Report to Commissioner of Patents the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,478,439 B2. (nmg) (Entered…2020 13 April 2021 1:20-cv-00403 835 Patent - Abbreviated New Drug Application(ANDA) Defendant External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.